Drug Trial Radar · NCT05442788
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Jul 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Sep 2, 2021
Primary completion
May 31, 2022
Study completion May 31, 2022
Sponsor
- Lead sponsor
- Huabo Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
HB0017 150mg or matching placeboBiological
Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
HB0017 300mg or matching placeboBiological
Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
HB0017 450mg or matching placeboBiological
Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent AE/SAEsTime frame: From baseline through week 20
- Elimination half-life (T1/2)Time frame: From baseline through week 20
- Area under drug-time curve (AUC)Time frame: From baseline through week 20
- Total clearance (CL/F)Time frame: From baseline through week 20
- Maximum serum concentrations (Cmax)Time frame: From baseline through week 20
- Mean retention time (MRT)Time frame: From baseline through week 20
- Volume of distribution (Vz/F)Time frame: From baseline through week 20
- Peak time(Tmax)Time frame: From baseline through week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.